- Safety reporting activities due to the COVID-19 pandemic: What are the pillars?
- Challenges measuring the effectiveness of risk minimisation measures
- How to design a patient centred pharmacovigilance system?
- Augmenting decision-making in PV through artificial intelligence
- What are the safety standards for pharmaceutical products?
- Automation in pharmacovigilance data processing: Do you trust artificial intelligence?
- How did the pandemic push pharmacovigilance to innovate?
- The impact of new technologies on PV system
9th Annual Risk Management and Pharmacovigilance Summit
26 - 27 October 2022 | Austria Trend Hotel Ananas
PAST SPEAKERS
SEE THE PREVIOUS SPEAKERS & CASE STUDIES
Andreas OSANGER
Director - Therapeutic Area Lead Nephrology
Monika MANSKE
Lead Quality Management and Deputy EEA QPPV
Stephanie TCHERNY
Global Head of Benefit-Risk Evaluation
Victoria BARTASEK
Senior Associate Director, Global Pharmacovigilance
Lisa STAGI
Drug Safety & Quality Head
CONFERENCE TOPICS 2022
LOOK AT THE TOPICS THAT WERE DISCUSSED
Designed for
Members of board, C-level, Senior/Global Vice Presidents, Directors, Heads of departments from the pharma industry involved in:
- Pharmacovigilance
- Risk Management
- PV Monitoring
- Signal Detection
- Data Collection
- Patient Safety
- Drug Safety
- Benefit-Risk Evaluation
- Quality Assurance
- Reporting and Data Collection
- Compliance
- Inspections
- Management Safety Data
- Lifecycle Management Quality
- Clinical Safety
CASE STUDY
How to Effectively Manage the Adverse Event Data from Digital Initiatives?
Victoria BARTASEK
Senior Associate Director, Global Pharmacovigilance
Lisa STAGI
Drug Safety & Quality Head
CASE STUDY
Patient Associations and Patients as Key Players in Pharmacovigilance: Reflections
The importance of proper awareness of patients and more involvement in PV activities is a key topic in the evolution on PV world. I propose to present the experience gained in this area through the work done also with the support of Patient associations.
- PV awareness from Patients
- Opportunities for more involvement of patients and a patient
centric approach to PV activities
CASE STUDY
Advances in Structured Benefit-Risk Assessment
This presentation aims to display the recent advances in Benefit-Risk field from new regulatory guidance, changes in BR methods to illustration of growing role of patient experience data into BR evaluation.
- Recent changes in Benefit-Risk regulatory landscape
- Improved use of Patient Experience Data for Benefit-Risk evaluation
- Trends and perspectives for the future in Benefit-Risk methods
Stephanie TCHERNY
Global Head of Benefit-Risk Evaluation
Andreas OSANGER
Director - Therapeutic Area Lead Nephrology
CASE STUDY
Building PV Partnerships for Drug Product Portfolios
CASE STUDY
From Call Center to Customer Engagement Center
We will guide you through our experience in the changing the concept of the Contact Center and implementation of the new strategy with the help of the technology.
• Creating the strategy
• New purpose and value drivers
• People and Technology
• Remote sales
Monika MANSKE
Lead Quality Management and Deputy EEA QPPV
”I really enjoyed learning from highly relevant presentations and lively discussions, and I will be definitely very happy to join the summit next year.
– Associate Director Global Regulatory Affairs, Translational Medicine & Devices, Merck
STAY UPDATED FOR THE 2023 EDITION
Provide Us With Your Contact Details and Our Team Will Get Back to You With All the Updates Regarding the Upcoming Edition of This Event.
